Tarsus Pharmaceuticals is evolving from a single-product company to a broader eye care platform, now generating positive cash flow. The company raised its 2026 net sales guidance for XDEMVY to $685–$705 million, expecting strong gross margins and $37 million in operating cash flow in the first half of 2026. Recent acquisitions in retina treatments come with milestone-based payments, reducing upfront risk and supporting future product launches. Despite this progress, Tarsus trades at a median sector valuation, suggesting the market may undervalue its late-stage pipeline beyond XDEMVY.
Tarsus Pharmaceuticals is the story's subject, with this snapshot from Pluang's health sector data as of Oct 06, 2026 19:45 WIB: Of 100 priced health stocks, 67 rose and 24 fell today. Notable movers include SYK at USD 278.00 with a 1-day change of -2.53% and 98% sell order activity, AZN at USD 160.35 up 2.44% with 95% buy order activity, and TWST at USD 209.50 up 2.20% with 92% sell order activity. Typical hold times range from 22 to 126 days on Pluang.
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
Apogee Enterprises reported strong fiscal Q2 results with adjusted earnings of $1.17 per share, nearly double the estimated $0.59, and revenue of $391.14 million, surpassing expectations of $362.6 million. This marks a continued trend of beating esti...
McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion in...
Ameriprise Financial has authorized an additional $5.5 billion for share repurchases through September 2028, supported by $2.1 billion in excess capital and $2.8 billion in liquidity. The company returned $1.9 billion to shareholders in H1 2026, incl...
